Anthrax clinical trials
The registry lists 64 studies for Anthrax across 8 countries. 11 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-24.
Status
- Completed
- 47
- Not yet recruiting
- 7
- Recruiting
- 4
- Terminated
- 3
- Suspended
- 1
- Active, not recruiting
- 1
Phase
- Phase 1
- 25
- Phase 2
- 13
- Phase 4
- 8
- Phase 3
- 3
Where
- United States
- 47
- France
- 2
- Korea, Republic of
- 2
- China
- 1
- Japan
- 1
- Canada
- 1
Who runs them
Emergent BioSolutions (17) · Elusys Therapeutics (6) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · PharmAthene, Inc. (3) · Altimmune, Inc. (2) · Taichung Veterans General Hospital (2) · VaxGen (2) · Biomedical Advanced Research and Development Authority (2)
Studies
Recruiting first, then most recently updated. Showing 50 of 64 — search for more.
- Combined Gastrointestinal Decontamination in Acute Severe PoisoningRecruitingNCT07201311Phase 21 country
- Cigarette Filter StudyRecruitingNCT07348679Not applicable1 country
- SGLT2 Inhibitor Utilization Re-perfusion TherapyNot yet recruitingNCT06858436Phase 4
- Observational Study of Raxibacumab in Sporadic Cases of Systemic AnthraxNot yet recruitingNCT07478471
- Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure ScenarioNot yet recruitingNCT02177721Phase 4
- Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic AnthraxNot yet recruitingNCT03569514
- A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax PatientsNot yet recruitingNCT03569553
- Activated CHARcoal in Poisoned Patient - Pilot TrialRecruitingNCT05471479Phase 41 country
- Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.Not yet recruitingNCT07268612
- A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe AnthraxRecruitingNCT063650731 country
- An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. AnthracisNot yet recruitingNCT03088111Phase 4
- Anthrax AV7909 Boost Evaluation StudyCompletedNCT05997264Phase 21 country
- Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated RecipientsCompletedNCT000503101 country
- Effect of Activated Charcoal on Serum Osmolality, Osmolal Gap, and Enzymatic Ethylene Glycol AssayActive, not recruitingNCT072200311 country
- The Effect of AC-134 in Chronic Kidney DiseasesCompletedNCT06441435Not applicable1 country
- VELOCITY: An Anthrax Vaccine Clinical StudyCompletedNCT03877926Phase 31 country
- Comparative Clinical Assessment of Charcoal and Conventional ToothbrushesCompletedNCT07563413Not applicable1 country
- Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral AnticoagulantsWithdrawnNCT02969746Phase 41 country
- Velocity 2: An Anthrax Vaccine and Antibiotics Clinical StudyCompletedNCT04067011Phase 21 country
- NasoShield Study of Safety and ImmunogenicityCompletedNCT03352466Phase 11 country
- NasoShield in Healthy Adults to Study Safety and ImmunogenicityCompletedNCT04415749Phase 11 country
- Ciprofloxacin BioThrax Co-Administration StudyCompletedNCT01753115Phase 21 country
- Anthrax AV7909 Liquid vs LyophilizedCompletedNCT04660201Phase 11 country
- Glyburide Advantage in Malignant Edema and Stroke - Remedy PharmaceuticalsCompletedNCT01794182Phase 21 country
- Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route ChangeCompletedNCT00119067Phase 41 country
- Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy AdultsCompletedNCT01491607Phase 31 country
- Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy AdultsCompletedNCT01263691Phase 11 country
- A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate VaccinesCompletedNCT01979406Phase 11 country
- Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)CompletedNCT00845650Phase 1/21 country
- Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine AdsorbedCompletedNCT02339155Phase 41 country
- A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose LevelsCompletedNCT01770743Phase 21 country
- Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human SerumCompletedNCT00448253Phase 11 country
- Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)CompletedNCT01202695Phase 11 country
- BioThrax® (Anthrax) Vaccine in Pregnancy RegistryCompletedNCT016533921 country
- Evaluation of the SRI B. Anthracis Lethal Factor Diagnostic SystemTerminatedNCT056728751 country
- A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109CompletedNCT01624532Phase 21 country
- A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy AdultsCompletedNCT04148118Phase 11 country
- Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI)CompletedNCT043204851 country
- BARDA Securing Anthrax Immunity For the ElderlyCompletedNCT03518125Phase 21 country
- Special Drug Use Investigation of Ciproxan Injection in PediatricsCompletedNCT025550591 country
- Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult VolunteersCompletedNCT01932242Phase 11 country
- Intramuscular Dose-Escalation Study With ETI-204 in Adult VolunteersCompletedNCT01932437Phase 11 country
- Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult VolunteersCompletedNCT01952444Phase 11 country
- Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult VolunteersCompletedNCT01929226Phase 11 country
- Febrile Whole Blood Specimen Collection and TestingCompletedNCT034980271 country
- An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With ReinjectionCompletedNCT02016963Phase 2/3
- Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult VolunteersCompletedNCT01453907Phase 11 country
- A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult SubjectsCompletedNCT02655549Phase 11 country
- Anthrax Vaccine Clinical TrialsCompletedNCT00114621Phase 11 country
- PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax VaccineCompletedNCT02239172Phase 11 country